PSMA-targeted therapy is a new type of treatment for prostate cancer that uses radioactive particles to target and kill cancer cells that express prostate-specific membrane antigen (PSMA). PSMA-targeted therapy has been shown to be very effective in treating advanced prostate cancer, and it is currently being evaluated in clinical trials for earlier-stage disease.
One of the most promising PSMA-targeted therapies is lutetium-177 (177Lu)-PSMA-617. 177Lu-PSMA-617 is a radioactive drug that is injected into the bloodstream and binds to PSMA proteins on the surface of prostate cancer cells. The radioactive particles then kill the cancer cells.
In clinical trials, 177Lu-PSMA-617 has been shown to shrink prostate tumors and prolong survival in patients with advanced prostate cancer. 177Lu-PSMA-617 is also relatively well-tolerated, with most patients experiencing only mild side effects.